Loading...
 
Mediterr J Rheumatol 2022;33(Suppl 1):142-9
Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment?
Authors Information
  1. Rheumatology Department, Reina Sofia University Hospital, Maimoindes Institute of Biomedical Research from Cordoba, Cordoba, Spain
  2. Rheumatology Department, Cochin Hospital, Paris, France
  3. Rheumatology Department, Saint-Joseph University, Beirut, Lebanon
  4. Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon
References
  1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
  2. Moll JM, Haslok I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 1974;53:343-64.
  3. López-Medinda C, Moltó A, Sieper J, Duruöz T, Kiltz U, Elzorkany B, et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 2021;71(1):e001450.
  4. Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol 2009;36:2744-50.
  5. Michelena X, Poddubnyy D, Marzo-Ortega H. Axial Psoriatic Arthritis: A distinct clinical entity in search of a definition. Rheum Dis Clin North Am 2020;46(2):327-41.
  6. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 2018;14:363-71.
  7. Hanly JG, Russel ML, Gladman DD. Psoriatic spondyloarthropathy: a long term prospective study. Ann Rheum Dis 1988;47:386-93.
  8. Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med 1977;46:411-25.
  9. Gladman DD, Brubacher B, Buskila D, Langevitz P, Farewell VT. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin Invest Med 1993;16:1-7.
  10. Gladman DD. Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007;9:455-60.
  11. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for medication of the New York criteria. Arthritis Rheum 1984;27:361-8.
  12. Lubrano E, Parsons WJ, Marchesoni A, Olivieri I, D’Angelo S, Cauli A, et al. The definition and measurement of axial psoriatic arthritis. J Rheumatol 2015;93:40-2.
  13. Feld J, Chandran V, Gladman D. What is axial psoriatic arthritis? J Rheumatol 2018;45:12.
  14. Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vargas R, Collantes-Estévez E, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis international society (ASAS). Ann Rheum Dis 2009;68(6):784-8.
  15. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016;2563-74.
  16. Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 2017;76:701-7.
  17. Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol 2018;45:10.
  18. López-Medina C, Ortega-Castro R, Castro-Villegas MC, Font-Ugalde P, Puche-Larrubia MA, Gómez-García I, et al. Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONSER registry. Rheumatology (Oxford) 2021;60(3):1125-36.
  19. Feld J, Ye JY, Chandran V, Inman RD, Haroon N, Cook R, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology 2020;59:1340-6.
  20. Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O. Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. Clin Exp Rheumatol 2017;35:270-6.
  21. Queiro R, Sarasqueta C, Belzunegui J, González C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 2002;31:413-8.
  22. Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2281-5.
  23. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(1):18-24.
  24. Calin A, Garret S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.
  25. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311-5.
  26. Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, Tasende JA, Fernández-López JC, Villar NO, et al. Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res 2010;62:78-85.
  27. Benavent D, Plasencia-Rodriguez C, Franco-Gómez K, Nieto R, Monjo-Henry I, Piteado D, et al. Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum? Ther Adv Musculoskelet Dis 2020;12:1-8.
  28. Hanly JG, Russell ML, Gladman DD. Psoriatic spondyloarthropathy: a long-term prospective study. Ann Rheum Dis 1988;47:386-93.
  29. Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a long-term prospective study. J Rheumatol 2009;36:2744-50.
  30. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
  31. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004;43:85-8.
  32. Castillo-Gallego C, Aydin SZ, Emery P, McGonagle DG, Marzo-Ortega H. Brief report: magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum 2013;65:2274–8.
  33. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-40.
  34. Salvarani C, Macchioni P, Cremonesi T, Mantovani W, Battistel B, Rossi F, et al The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study. Ann Rheum Dis 1992;51:73-7.
  35. Haddad A, Thavaneswaran A, Toloza S, Toloza S, Chandran V, Gladman DD. Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. J Rheumatol 2013;40:1367–73.
  36. Lubrano E, Marchesoni A, Olivieri I, D’Angelo S, Spadaro A, Parsons WJ, et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 2009;27:977-80.
  37. Lubrano E, Marchesoni A, Olivieri I, D’Angelo S, Spadaro A, Parsons WJ, et al. Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol 2009;36:1006-11.
  38. Maldonado-Ficco H, Sheane BJ, Thavaneswaran A, Chanran V, Gladman DD. Magnetic resonance imaging in psoriatic arthritis. J Clin Rheumatol 2017;23:243-5.
  39. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-91.
  40. Singh J, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019;71(1):5-32.
  41. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.
  42. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felques ML, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060-71.
  43. Haroon M, Ahmad M, Baig MN, Mason O, Rice J, FitzGerald O. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther 2018;20:73.
  44. Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D’Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2020;0:1-9.
  45. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48.
  46. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373(14):1329-39.
  47. Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol 2021;73(1):110-20.
  48. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. N Engl J Med 2014;371(4):326-38.
  49. Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet 2020; 395(10230):1115-25.
  50. Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet 2020;395(10230):1126-36.
  51. Mease PJ, McInnes I, Eaton K, Peterson S, Disher T, Chakravarty S, et al. Comparative efficacy of guselkumab in patients with psoriatic arthritis: results from systematic literature review and network meta-analysis [abstract]. Arthritis Rheumatol 2020;72(suppl 10).
  52. Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 2016;43:918-23.
  53. Rios Rodriguez V, Poddubnyy D. Tumor necrosis factor-a (TNFa) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therpya. Ther Adv Musculoskel Dis 2017;9(8):197-210.
  54. Lubrano E, Spadaro A, Marchesoni A, Olivieri I, Scarpa R, D’Angelo S, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011;29:80-4.